Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1996 Oct;70(10):7327–7330. doi: 10.1128/jvi.70.10.7327-7330.1996

Lymphoproliferative responses after infection with human parvovirus B19.

A von Poblotzki 1, C Gerdes 1, U Reischl 1, H Wolf 1, S Modrow 1
PMCID: PMC190798  PMID: 8794392

Abstract

Immunity after infection with the parvovirus B19 is assumed to be conferred by a humoral immune response with development of neutralizing antibody. In contrast, little is known about the nature of T-cell-mediated responses to parvovirus B19 infection in humans. We used recombinant proteins VP1, VP2, and NS1, as well as a recombinant VP1-specific amino-terminal sequence, to test the proliferative responses of peripheral blood mononuclear cells after infection of otherwise healthy individuals with parvovirus B19. These proteins were used as antigens for the stimulation of freshly isolated cells. The results show that a B19 virus-specific cellular immunity develops that is directed against the capsid proteins VP1 and VP2. We also demonstrate that viral determinants are presented to CD4+ T cells by HLA class II molecules.

Full Text

The Full Text of this article is available as a PDF (175.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson L. J. Human parvoviruses. J Infect Dis. 1990 Apr;161(4):603–608. doi: 10.1093/infdis/161.4.603. [DOI] [PubMed] [Google Scholar]
  2. Anderson M. J., Jones S. E., Fisher-Hoch S. P., Lewis E., Hall S. M., Bartlett C. L., Cohen B. J., Mortimer P. P., Pereira M. S. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet. 1983 Jun 18;1(8338):1378–1378. doi: 10.1016/s0140-6736(83)92152-9. [DOI] [PubMed] [Google Scholar]
  3. Bogedain C., Wolf H., Modrow S., Stuber G., Jilg W. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol. 1995 Aug;69(8):4872–4879. doi: 10.1128/jvi.69.8.4872-4879.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen B. J., Buckley M. M., Clewley J. P., Jones V. E., Puttick A. H., Jacoby R. K. Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis. 1986 Oct;45(10):832–838. doi: 10.1136/ard.45.10.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frickhofen N., Abkowitz J. L., Safford M., Berry J. M., Antunez-de-Mayolo J., Astrow A., Cohen R., Halperin I., King L., Mintzer D. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990 Dec 15;113(12):926–933. doi: 10.7326/0003-4819-113-12-926. [DOI] [PubMed] [Google Scholar]
  6. Frickhofen N., Young N. S. Persistent parvovirus B19 infections in humans. Microb Pathog. 1989 Nov;7(5):319–327. doi: 10.1016/0882-4010(89)90035-1. [DOI] [PubMed] [Google Scholar]
  7. Graham S., Wang E. C., Jenkins O., Borysiewicz L. K. Analysis of the human T-cell response to picornaviruses: identification of T-cell epitopes close to B-cell epitopes in poliovirus. J Virol. 1993 Mar;67(3):1627–1637. doi: 10.1128/jvi.67.3.1627-1637.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kurtzman G. J., Cohen B. J., Field A. M., Oseas R., Blaese R. M., Young N. S. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest. 1989 Oct;84(4):1114–1123. doi: 10.1172/JCI114274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kurtzman G., Frickhofen N., Kimball J., Jenkins D. W., Nienhuis A. W., Young N. S. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989 Aug 24;321(8):519–523. doi: 10.1056/NEJM198908243210807. [DOI] [PubMed] [Google Scholar]
  10. Lovett A. E., McCarthy M., Wolinsky J. S. Mapping cell-mediated immunodominant domains of the rubella virus structural proteins using recombinant proteins and synthetic peptides. J Gen Virol. 1993 Mar;74(Pt 3):445–452. doi: 10.1099/0022-1317-74-3-445. [DOI] [PubMed] [Google Scholar]
  11. McCarthy M., Lovett A., Kerman R. H., Overstreet A., Wolinsky J. S. Immunodominant T-cell epitopes of rubella virus structural proteins defined by synthetic peptides. J Virol. 1993 Feb;67(2):673–681. doi: 10.1128/jvi.67.2.673-681.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Naides S. J., Scharosch L. L., Foto F., Howard E. J. Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience. Arthritis Rheum. 1990 Sep;33(9):1297–1309. doi: 10.1002/art.1780330901. [DOI] [PubMed] [Google Scholar]
  13. Pattison J. R., Jones S. E., Hodgson J., Davis L. R., White J. M., Stroud C. E., Murtaza L. Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet. 1981 Mar 21;1(8221):664–665. doi: 10.1016/s0140-6736(81)91579-8. [DOI] [PubMed] [Google Scholar]
  14. Pont J., Puchhammer-Stöckl E., Chott A., Popow-Kraupp T., Kienzer H., Postner G., Honetz N. Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol. 1992 Feb;80(2):160–165. doi: 10.1111/j.1365-2141.1992.tb08894.x. [DOI] [PubMed] [Google Scholar]
  15. Reid D. M., Reid T. M., Brown T., Rennie J. A., Eastmond C. J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet. 1985 Feb 23;1(8426):422–425. doi: 10.1016/s0140-6736(85)91146-8. [DOI] [PubMed] [Google Scholar]
  16. Schwarz T. F., Roggendorf M., Hottenträger B., Deinhardt F., Enders G., Gloning K. P., Schramm T., Hansmann M. Human parvovirus B19 infection in pregnancy. Lancet. 1988 Sep 3;2(8610):566–567. doi: 10.1016/s0140-6736(88)92684-0. [DOI] [PubMed] [Google Scholar]
  17. Serjeant G. R., Serjeant B. E., Thomas P. W., Anderson M. J., Patou G., Pattison J. R. Human parvovirus infection in homozygous sickle cell disease. Lancet. 1993 May 15;341(8855):1237–1240. doi: 10.1016/0140-6736(93)91145-c. [DOI] [PubMed] [Google Scholar]
  18. Simons J., Kutubuddin M., Chow M. Characterization of poliovirus-specific T lymphocytes in the peripheral blood of Sabin-vaccinated humans. J Virol. 1993 Mar;67(3):1262–1268. doi: 10.1128/jvi.67.3.1262-1268.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. White D. G., Woolf A. D., Mortimer P. P., Cohen B. J., Blake D. R., Bacon P. A. Human parvovirus arthropathy. Lancet. 1985 Feb 23;1(8426):419–421. doi: 10.1016/s0140-6736(85)91145-6. [DOI] [PubMed] [Google Scholar]
  20. von Poblotzki A., Gigler A., Lang B., Wolf H., Modrow S. Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol. 1995 Mar;76(Pt 3):519–527. doi: 10.1099/0022-1317-76-3-519. [DOI] [PubMed] [Google Scholar]
  21. von Poblotzki A., Hemauer A., Gigler A., Puchhammer-Stöckl E., Heinz F. X., Pont J., Laczika K., Wolf H., Modrow S. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis. 1995 Nov;172(5):1356–1359. doi: 10.1093/infdis/172.5.1356. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES